Clinical Trial Update: Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 [Phase 1]

View source ↗

Summary

Phase 1 substudy update evaluating Ad-RTS-hIL-12 with Veledimex in recurrent or progressive glioblastoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Ad-RTS-hIL-12 (Adenoviral vector encoding human interleukin-12 under Rheostatic Transcriptional System)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Glioblastoma | Phase 1 | Status: COMPLETED | Results posted: 2025-08-28